Deal Watch: Takeda Caps Busy Deal-Making Week With Three Transactions
Executive Summary
Takeda invests further in rare diseases with a pair of deals, while also divesting some non-core assets via a joint venture agreement with Roivant. AstraZeneca also moved on from some non-core business in a deal with South Africa's Aspen.